Summary
The symptoms of peripheral arterial occlusive disease (PAOD) can be attributed to tissue hypoxia. Vasoactive drugs such as buflomedil improve microcirculatory blood perfusion despite the presence of large artery occlusions. In this open study, the safety and clinical efficacy of Bufedil® long (buflomedil 600mg delayed action tablets; Abbott Laboratories) were evaluated in 3541 private practice patients with PAOD (Fontaine Stage II a/b). After 8 weeks of therapy, pain-free walking distance increased or doubled for 89.5% of the patients. Claudication pain intensity and the sensation of cold in the lower extremities were reduced in approximately 88% of the patients. Despite the multimorbidity and polypharmacy in this patient population, drug interactions between buflomedil and concurrent medication were not observed. Only 4 patients discontinued the study as a result of adverse events, most of which were mild and transient in nature. Approximately 89% of the patients judged drug compatibility to be good or very good with < 1% reporting poor tolerability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachand RT, Dubourg AY. A review of long-term safety data with buflomedil. Journal of International Medical Research 18: 245–252, 1990
Barker JJ, Menger MD, Sack FU, Messmer K. Nutritive Hautdurchblutung bei partieller Ischamie: Wirkung verschiedener vasoaktiver Substanzen. Vasa 17: 37–41, 1988
Diamantopoulus EJ, Grammoustianos CS, Stavreas NP, Raptis SA, et al. Controlled trial of buflomedil in diabetic peripheral occlusive arterial disease. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 80–84, W. Zuckschwerdt Verlag, Munich, 1989
Diehm C. Begleiterkrankungen und Risikofaktoren bei peripherer arterieller Verschlusskrankheit. In Trubestein G (Hrsg.) Periphere und zentrale Durchblutungsstorungen pp. 28–34, peri med fach buch, Stuttgart, 1988
Diehm C. Pravention der peripheren arteriellen Verschlusskrankheit. In Senn E, Emst E (Hrsg.) Medikamentose und physikalische Therapie der arteriellen Verschlusskrankheit, pp. 71–84, W. Zuckschwerdt Verlag, Munich, 1987
Ehrly AM, Saeger-Lorenz K. Einfluss von Buflomedil i.v. auf den Belastungssauerstoffdruck im Muskelgewebe von Patienten mit Claudication intermittens. Medwelt 40: 1–4, 1989
Fonseca V, Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, et al. Double-blind placebo-controlled trial of buflomedil in intermittent claudication. International Journal of Clinical Pharmacology Research 8: 377–381, 1988
Forst H, Fujita Y, Racenberg J, Bruckner U, Weiss T, et al. Skelettmuskeldurchblutung bei arterieller Verschlusskrankheit; wirkung verschiedener Therapieverfahren. In Hammersen F, Messmer K (Hrsg.) Die Mikrozirkulation des Skelettmuskels, pp. 119–135, Karger Verlag, Basle, 1984
Gottstein P. Additive Wirkung von Buflomedil bei gleichzeitigem Training. Zeitschrift für Allgemeinmedizin 63: 836–839, 1987
Grus JD. Operative Therapie im fortgeschrittenen Stadium der AVK (Stadium III und IV). In Trubestein G (Hrsg.) Therapie der arteriellen Verschlusskrankheit, pp. 74–79, W. Zuckschwerdt Verlag, Munich, 1986
Heidrich H. Periphere arterielle Verschlusskrankheit. Therapiewoche 39: 1721–1724, 1989a
Heidrich H. Rationelles Therapiekonzept 1989 in der Behandlung peripherer arterieller Durchblutungsstorungen. Therapiewoche 39: 1809, 1989b
Intaglietta M. Vasomotion: physiology and pathology. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 38–43, W. Zuckschwerdt Verlag, Munich, 1989
Lewis DH. Microcirculation and rheology: an introduction. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 1–5, W. Zuckschwerdt Verlag, Munich, 1989
Lowe GDO, Andersen J, Lockhart J. Red cell aggregation and deformation in ischemia: effects of buflomedil in vitro. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 6–11, W. Zuckschwerdt Verlag, Munich, 1989
Marshall M. Epidemiologie der arteriellen Verschluskrankheit. In Kluken N (Hrsg.) Diagnose und Therapie der arteriellen Verschlusskrankheit, Vol. 33, pp. 1–14, 1986
Racenberg J, Intaglietta M, Messmer K. Die Wirkungen des vasoaktiven Medikamentes Buflomedil bei der arteriellen Verschlusskrankheit. Fortschritte der Medizin 41: 1926–1930, 1982
Ranft J. Stellenwert moderner Mikrozirkulationsuntersuchungen. Therapiewoche 39: 1746–1756, 1989
Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bulletin of the World Health Organization 27: 645, 1962
Sack FU, Zeintl H, Galla TJ, Messmer K. Dynamics of leucocyte adhesion to the microvascular endotheium in response to ischemia: effect of buflomedil. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 22–30, W. Zuckschwerdt Verlag, Munich, 1989
Sunder-Plassmann L. Bedeutung des Kollateralwiderstandes bei arterieller Verschlusskrankheit. Therapiewoche 33: 93–100, 1983
Trubestein G, Balzer K, Bisler H, Kluken N, Mahfoud Y, et al. Buflomedil bei arterieller Verschlusskrankheit. In Trubestein G (Hrsg.) Konservative Therapie arterieller Durchblutungsstorungen, pp. 75–81, Thieme Verlag, Stuttgart, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, J. The Safety and Efficacy of Bufedil® Long (Buflomedil 600mg Delayed Action Tablets) in Patients with Peripheral Arterial Occlusive Disease (Fontaine Stage II a/b). Drug Invest. 3, 266–269 (1991). https://doi.org/10.1007/BF03259576
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259576